TNF and rheumatoid arthritis: Among the anti-TNF (+/-DMARD) group with RA, the users of adalimumab and etanercept were found to have persistence rates of 67.2% and 65.8%; whereas 46.6% of the patients persisted in their therapies with infliximab in the first year (95%CI 10.9–21.8% for difference between adalimumab and infliximab, and 95%CI 10.3–21.8% for difference between etanercept and infliximab).